$0.00
−84.62%Oct 15, 2026, 12:00 UTC
Jasper Therapeutics completed enrollment in the IgA nephropathy cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104).
Source:Oct 7, 2026, 12:00 UTC
Jasper Therapeutics commenced an offer to purchase all outstanding warrants issued in its September 18, 2025 public offering for $0.324 in cash per warrant; tendered warrants will be retired and cancelled.
Source:Sep 28, 2026, 20:57 UTC
Jasper Therapeutics, Inc. announced that Chief Financial Officer Herb Cross departed effective October 9, 2026, with Jeet Mahal, Rick Ruiz and Matthew Ros appointed to interim finance and secretary roles.
Sep 15, 2026, 20:05 UTC
Jasper Therapeutics appointed Lisa Pitt as Senior Vice President, Regulatory Affairs and Shiguang Liu as a clinical executive.
Source:Aug 14, 2026, 00:00 UTC
Jasper Therapeutics reported a net loss of $2.76 million for Q2 2026, with diluted loss per share of $0.10, and cash and cash equivalents of $7.3 million as of June 30, 2026.
Jul 17, 2026, 00:00 UTC
Jasper Therapeutics raised $132 million in a private stock offering.
Source:Jul 17, 2026, 00:00 UTC
Jasper Therapeutics acquired Kira Pharmaceuticals via a reverse triangular merger, with consideration of Jasper common and convertible preferred stock.